1 |
WALLS A C, PARK Y J, TORTORICI M A, et al.. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell, 2020, 181(2): 281-292.
|
2 |
CRUZ-TERAN C, TIRUTHANI K, MCSWEENEY M, et al.. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy[J]. Adv. Drug Deliv. Rev., 2021, 169: 100-117.
|
3 |
WU Y, LI C, XIA S, et al.. Identification of human single-domain antibodies against SARS-CoV-2[J]. Cell Host Microbe., 2020, 27(6): 891-898.
|
4 |
TIAN X, LI C, HUANG A, et al.. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody[J]. Emerg. Microbes. Infec., 2020, 9(1): 382-385.
|
5 |
杨高松,马东杰.呼吸道传染病治疗中抗体药物的研发进展[J]. 生物技术进展, 2020, 10(5): 441-447.
|
6 |
WU Y, JIANG S, YING T. Single-domain antibodies aAs therapeutics against human viral diseases[J/OL]. Front. Immunol., 2017, 8(1802)[2017-12-13]. .
|
7 |
BUSS N A, HENDERSON S J, MCFARLANE M, et al.. Monoclonal antibody therapeutics: history and future[J]. Curr. Opin. Pharmacol., 2012(12): 615-622.
|
8 |
LAWSON A D. Antibody-enabled small-molecule drug discovery[J]. Nat. Rev. Drug Discov., 2012, 11(7): 519-525.
|
9 |
YUAN M, WU N C, ZHU X, et al.. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV[J]. Science, 2020, 368(6491): 630-633.
|
10 |
STEELAND S, VANDENBROUCKE R E, LIBERT C. Nanobodies as therapeutics: big opportunities for small antibodies[J]. Drug Discov. Today, 2016, 21(7): 1076-1113.
|
11 |
BOULENOUAR H, AMAR Y, BOUCHOUTROUCH N, et al.. Nanobodies and their medical applications[J/OL]. Genet. Mol. Res., 2020, 19:gmr184521[2020-05-26]. .
|
12 |
HUO J, LE BAS A, RUZA R R, et al.. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2[J]. Nat. Struct. Mol. Biol., 2020, 27(9): 846-854.
|
13 |
SAMARANAYAKE H, WIRTH T, SCHENKWEIN D, et al.. Challenges in monoclonal antibody-based therapies[J]. Ann. Med., 2009, 41: 322-331.
|
14 |
BANNAS P, HAMBACH J, KOCH-NOLTE F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics[J/OL]. Front. Immunol., 2017, 8: 1603[2017-11-22]. .
|
15 |
HASSANZADEH-GHASSABEH G, DEVOOGDT N, DE AUW P, et al.. Nanobodies and their potential applications[J]. Nanomedicine, 2013, 8(6): 1013-1026.
|
16 |
VAN HEEKE G, ALLOSERY K, De BRABANDERE V, et al.. Nanobodies® as inhaled biotherapeutics for lung diseases[J]. Pharmacol. Ther., 2017, 169: 47-56.
|
17 |
LIU Y, HUANG H. Expression of single-domain antibody in different systems[J]. Appl. Microbiol. Biotechnol., 2018, 102(2): 539-551.
|
18 |
VEGGIANI G, DE MARCO A. Improved quantitative and qualitative production of single-domain intrabodies mediated by the co-expression of Erv1p sulfhydryl oxidase[J]. Protein Expr. Purif., 2011, 79(1): 111-114.
|
19 |
XUE X, FAN X, QU Q, et al.. Bioscreening and expression of a camel anti-CTGF VHH nanobody and its renaturation by a novel dialysis-dilution method[J/OL]. AMB Express, 2016, 6(1): 72[2016-09-13]. .
|
20 |
张云鹏,温彤,姜伟.大肠杆菌和酵母表达系统的研究进展[J]. 生物技术进展, 2014, 4(6): 389-393.
|
21 |
KUO M M, NGUYEN P H, JEON Y H, et al.. MB109 as bioactive human bone morphogenetic protein-9 refolded and purified from E.coli inclusion bodies[J/OL]. Microb. Cell Fact. 2014, 13(1): 29[2014-01-24]. .
|
22 |
LOPES A M, SANTOS-EBINUMA V C, NOVAES L C, et al.. LPS-protein aggregation influences protein partitioning in aqueous two-phase micellar systems[J]. Appl. Microbiol. Biotechnol., 2013, 97(14): 6201-6209.
|